CSL Vifor (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CSL Vifor" in English language version.

refsWebsite

Global rank English rank

low place

7,595^th place

49^th place

47^th place

2,149^th place

1,198^th place

2globenewswire.com

2,614^th place

1,549^th place

2swissbiotech.org

low place

low place

2pharmaceutical-technology.com

low place

low place

99^th place

77^th place

2businesswire.com

615^th place

407^th place

2thepharmaletter.com

low place

low place

4^th place

4^th place

1handelszeitung.ch

7,752^nd place

low place

1fiercepharma.com

low place

8,921^st place

1viforpharma.com

low place

low place

1european-biotechnology.com

low place

low place

low place

low place

low place

low place

low place

low place

1pharmaphorum.com

low place

low place

1newcastle.edu.au

low place

low place

1asn-online.org

low place

low place

low place

low place

2^nd place

2^nd place

afr.com

Redrup, Yolanda (2022-02-18). "Vifor results show strength as CSL tender period nears end". Australian Financial Review. Retrieved 2022-02-28.
Lafrenz, Carrie (2021-12-14). "CSL had eye on Vifor Pharma for a decade". Australian Financial Review. Retrieved 2022-06-28.

asn-online.org

"Indirect Comparison of Treatments for Secondary Hyperparathyroidism Through a Network Meta-Analysis". ASN-Online. 2020-10-22. Retrieved 2022-05-20.

biospace.com

"Vifor Pharma reports sustained growth in 2021". 2022-02-17. Retrieved 2022-11-20.
Terry, Mark (2021-11-22). "Vifor Pharma Doubles Down on Kidney Disease with New Acquisitions". biospace.com. Retrieved 2022-02-28.
"Vifor Pharma reports sustained growth in 2021". Biospace. 2022-02-17. Retrieved 2022-05-10.
"Vifor Pharma reports sustained growth in 2021". Biospace. 2022-02-17. Retrieved 2022-05-20.
"fizer's Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market". Biospace. 2018-07-31. Retrieved 2022-05-20.
"Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients". Biospace. 2022-02-25. Retrieved 2022-05-20.
McKenzie, Heather (2021-12-14). "CSL Tenders Offer to Buy Vifor Pharma for $11.7 Billion". Biospace. Retrieved 2022-05-20.

bloomberg.com

"Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance". Bloomberg News. 2021-08-21. Retrieved 2022-11-20.
"Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance". Bloomberg. 2021-08-05. Retrieved 2022-05-10.

businesswire.com

"Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World's First Research Professorship for Nanopharmaceutical and Regulatory Science". Businesswire. 2019-05-26. Retrieved 2022-06-28.
"Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance". Australian Financial Review. 2020-03-12. Retrieved 2022-06-28.

doi.org

Manolova, Vania; Nyffenegger, Naja; Flace, Anna; Altermatt, Patrick; Varol, Ahmet; Doucerain, Cédric; Sundstrom, Hanna; Dürrenberger, Franz (2019-10-22). "Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia". The Journal of Clinical Investigation. 130 (1): 491–506. doi:10.1172/JCI129382. PMC 6934209. PMID 31638596. Retrieved 2019-10-22.

efpia.eu

"Membership". efpia.eu. Retrieved 2021-11-28.

european-biotechnology.com

"Vifor Pharma in US$100m licence deal with Cara Therapeutics". 2020-10-21. Retrieved 2022-11-20.

fiercepharma.com

Kanstein, Fraiser (2022-08-02). "After delay, CSL's $11.7B deal for Vifor poised to close next week". Fiercepharma. Retrieved 2022-12-29.

fool.com.au

"CSL share price climbs as $16 billion Vifor acquisition becomes effective". 2022-08-09. Retrieved 2022-11-20.

globenewswire.com

"Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food" (Press release). 2018-05-08. Retrieved 2022-11-20.
"Anemia Treatment Drugs: 2019 Global Market Study; Analyzed". globenewswire.com (Press release). 26 April 2019. Retrieved 2021-11-28.

handelszeitung.ch

"Der reichste Ebener aller Zeiten". Handelszeitung (in German). 2021-12-14. Retrieved 2022-05-10.

jci.org

Manolova, Vania; Nyffenegger, Naja; Flace, Anna; Altermatt, Patrick; Varol, Ahmet; Doucerain, Cédric; Sundstrom, Hanna; Dürrenberger, Franz (2019-10-22). "Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia". The Journal of Clinical Investigation. 130 (1): 491–506. doi:10.1172/JCI129382. PMC 6934209. PMID 31638596. Retrieved 2019-10-22.

newcastle.edu.au

Patterson, Amanda; Johnson, Jacklyn (2020-11-18). "I've been diagnosed with iron deficiency, now what?". Hippocampus. Retrieved 2022-05-20.

nih.gov

ncbi.nlm.nih.gov

Manolova, Vania; Nyffenegger, Naja; Flace, Anna; Altermatt, Patrick; Varol, Ahmet; Doucerain, Cédric; Sundstrom, Hanna; Dürrenberger, Franz (2019-10-22). "Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia". The Journal of Clinical Investigation. 130 (1): 491–506. doi:10.1172/JCI129382. PMC 6934209. PMID 31638596. Retrieved 2019-10-22.

pubmed.ncbi.nlm.nih.gov

Manolova, Vania; Nyffenegger, Naja; Flace, Anna; Altermatt, Patrick; Varol, Ahmet; Doucerain, Cédric; Sundstrom, Hanna; Dürrenberger, Franz (2019-10-22). "Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia". The Journal of Clinical Investigation. 130 (1): 491–506. doi:10.1172/JCI129382. PMC 6934209. PMID 31638596. Retrieved 2019-10-22.

pharmaceutical-technology.com

"Vifor Pharma and Fresenius Kabi form joint venture in China". 2020-02-20. Retrieved 2022-11-20.
"Vifor Pharma and Fresenius Kabi form joint venture in China". Pharmaceutical Technology. 2020-02-20. Retrieved 2022-05-10.

pharmaphorum.com

Staines, Richard (2020-02-20). "Vifor forges iron drug partnership with Fresenius in China". Pharmaphorum. Retrieved 2022-06-28.

publicnow.com

docs.publicnow.com

"Fairness Opinion Vifor Pharma". IFBC. 2022-01-17. Retrieved 2022-05-20.

reuters.com

"Galenica says to offer $915 million for Aspreva". Reuters. 18 October 2007. Retrieved 2021-11-28.
"Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split". Reuters. 21 July 2016. Retrieved 2021-11-28.
Nainan, Nikhil; Koltrowitz, Silke; Murdoch, Scott; Murdoch, Scott (14 December 2021). "Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln". Reuters.
Nainan, Nikhil; Koltrowitz, Silke; Murdoch, Scott (2021-12-14). "Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln". Reuters. Retrieved 2022-02-28.

swissbiotech.org

"Media release: Swiss biotechnology – Investments at record level and outstanding success stories". Swiss Biotech. Retrieved 2021-11-28.
"Vifor Fresenius Medical Care Renal Pharma". Swissbiotech. Retrieved 2022-05-10.

thepharmaletter.com

"Vifor Pharma jumps further into vascular calcification field, through acquisitions". The Pharma Letter. 2021-11-22. Retrieved 2022-06-28.
"Vifor Pharma's IV Ferinject reduces the need for further anemia treatment in kidney disease patients". ASN-Online. 2013-07-10. Retrieved 2022-05-20.

viforpharma.com

"Vifor Pharma Group announces successful sale of OM Pharma". www.viforpharma.com. Retrieved 2020-10-04.